Conventional Home Exercise Programs Versus Electronic Home Exercise Versus Artificial Intelligence "Virtual Therapy" for Anterior Knee Pain
Patellofemoral Pain Syndrome
About this trial
This is an interventional treatment trial for Patellofemoral Pain Syndrome focused on measuring Knee pain, Anterior knee pain, Patellofemoral, Patellofemoral syndrome, Runners knee
Eligibility Criteria
Inclusion Criteria:
- Age 18-64 with anterior knee pain
- Have computer access
- Cleared for exercise by a medical professional, if not possible or a medical professional on the study team over the phone and the PAR-Q (Physical Activity Readiness Questionnaire)
- Have consented to participate in the trial
Exclusion Criteria:
- Age < 18 or > 64
- Screened as unsafe for exercise by a medical professional or the, study team and/ or Screened out by the PAR-Q
- Does not consent to the trial
Sites / Locations
- Simpletherapy
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Experimental
PDF exercise sheets
Limited Exercise Videos
Algorithm based Exercise Videos
Participants in this arm will receive a PDF sheet of 6 exercises that are commonly administered for the treatment of anterior knee pain. They will be asked to perform the exercises three times a week for 6 weeks. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
Participants in this arm will receive the same six exercises as provided in the PDF sheet in arm 1 in a video format. They will be asked to perform the exercises three times per week for 6 weeks. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
Participants in this arm will be provided a 6 week regimen of exercise videos for their anterior knee pain. Following each exercise session, the participant will be asked for their input concerning each exercise. The algorithm will adjust the exercise regimen for the next session based on the participants input. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.